Endometriosis is a chronic inflammatory gynecological condition that affects millions of women and people with uteri globally, with limited available treatments. In this work, we explore using ionic liquid (IL)-coated …
Gynecologic disorders, including infections, sterile inflammatory diseases, endocrine abnormalities, and malignancies, share a common signature of dysregulated immunity within a uniquely hormone-responsive reproductive tract. Neutrophil extracellular traps (NETs) are increasingly …
Endometriosis (EMs) is a gynecological inflammatory disease that depends on estrogen. Its chief symptoms include dysmenorrhea, chronic pelvic pain, reduced fertility, and pelvic masses. Although various hormonal therapies and surgical …
Aberrant vascular endothelial growth factor (VEGF)-driven angiogenesis is central to the establishment and persistence of endometriosis. Although numerous anti-angiogenic compounds have been tested, evidence remains fragmented, and no comparative framework …
Endocrine disrupting chemicals (EDCs) have been associated with disorders affecting female reproductive health, although the precise causal connections and underlying pathways between these substances and such disorders remain incompletely elucidated. …
Growing evidence suggests that women with endometriosis may be particularly vulnerable to disordered eating behaviors (DEBs) and clinically defined eating disorders (EDs). This narrative review aims at integrating and critically …
Endometriosis is characterized by the ectopic implantation of endometrial tissue affecting reproductive-aged women. Available therapies have still unmet needs namely due to recurrence rates and systemic side effects. Emerging evidence …
Chronic low-grade inflammation is increasingly recognized as a contributing factor to female infertility. Elevated levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 are observed in ovarian conditions including …
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …